AMY-101
Modify Date: 2025-08-25 09:22:03
AMY-101 structure
|
Common Name | AMY-101 | ||
|---|---|---|---|---|
| CAS Number | 1427001-89-5 | Molecular Weight | 1789.11 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C83H117N23O18S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AMY-101AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2]. |
| Name | AMY-101 |
|---|
| Description | AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
KD: 0.5 nM (C3)[1]. |
| In Vivo | AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis[1]. AMY-101 can induce a long-lasting anti-inflammatory effect[1]. AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction[1]. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7 – 15 years old; 5.0 – 7.6 kg body weight)[1]. Dosage: 0.1 mg/site; 50 μL of 2 mg/mL solution. Administration: Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) Result: Does not cause irritation in healthy gingiva. |
| References |
| Molecular Formula | C83H117N23O18S2 |
|---|---|
| Molecular Weight | 1789.11 |